Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABT Stock Forecast 2025-2026
$131.30
Current Price
$229.46B
Market Cap
Buy 19
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to ABT Price Targets
+21.1%
To High Target of $159.00
+9.0%
To Median Target of $143.12
-8.5%
To Low Target of $120.12
ABT Price Momentum
-2.6%
1 Week Change
+1.5%
1 Month Change
+26.3%
1 Year Change
+16.1%
Year-to-Date Change
-7.0%
From 52W High of $141.23
+31.7%
From 52W Low of $99.71
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Abbott (ABT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ABT and similar high-potential opportunities.
Latest ABT Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, ABT has a bullish consensus with a median price target of $143.12 (ranging from $120.12 to $159.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $131.30, the median forecast implies a 9.0% upside. This outlook is supported by 19 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 21.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABT Analyst Ratings
19
Buy
9
Hold
0
Sell
ABT Price Target Range
Low
$120.12
Average
$143.12
High
$159.00
Current: $131.30
Latest ABT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $145.00 |
| Apr 17, 2025 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $145.00 |
| Apr 17, 2025 | Jefferies | Matthew Taylor | Hold | Maintains | $137.00 |
| Apr 17, 2025 | Raymond James | Jayson Bedford | Outperform | Maintains | $142.00 |
| Apr 17, 2025 | Stifel | Rick Wise | Buy | Maintains | $145.00 |
| Apr 17, 2025 | Morgan Stanley | David Lewis | Equal-Weight | Maintains | $127.00 |
| Apr 17, 2025 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $147.00 |
| Apr 17, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $159.00 |
| Mar 10, 2025 | B of A Securities | Travis Steed | Buy | Maintains | $150.00 |
| Mar 4, 2025 | Citigroup | Joanne Wuensch | Buy | Maintains | $160.00 |
| Mar 4, 2025 | Goldman Sachs | David Roman | Buy | Maintains | $154.00 |
| Jan 27, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $158.00 |
| Jan 23, 2025 | UBS | Danielle Antalffy | Buy | Maintains | $148.00 |
| Jan 23, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $135.00 |
| Jan 23, 2025 | Wells Fargo | Lawrence Biegelsen | Overweight | Maintains | $136.00 |
| Jan 23, 2025 | Stifel | Rick Wise | Buy | Maintains | $135.00 |
| Jan 21, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $135.00 |
| Nov 5, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $149.00 |
| Oct 17, 2024 | Piper Sandler | Adam Maeder | Overweight | Maintains | $133.00 |
| Oct 17, 2024 | Morgan Stanley | David Lewis | Equal-Weight | Maintains | $117.00 |
Abbott Laboratories (ABT) Competitors
The following stocks are similar to Abbott based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Abbott Laboratories (ABT) Financial Data
Abbott Laboratories has a market capitalization of $229.46B with a P/E ratio of 17.1x. The company generates $42.34B in trailing twelve-month revenue with a 31.9% profit margin.
Revenue growth is +4.0% quarter-over-quarter, while maintaining an operating margin of +18.1% and return on equity of +30.6%.
Valuation Metrics
Market Cap
$229.46B
Enterprise Value
$238.18B
P/E Ratio
17.1x
PEG Ratio
25.6x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
+4.0%
Gross Margin
+56.9%
Operating Margin
+18.1%
Net Margin
+31.9%
EPS Growth
+8.2%
Financial Health
Cash/Price Ratio
+3.0%
Current Ratio
1.8x
Debt/Equity
27.1x
ROE
+30.6%
ROA
+6.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Abbott Laboratories (ABT) Business Model
About Abbott Laboratories
What They Do
Develops and produces healthcare and medical products.
Business Model
Abbott Laboratories generates revenue through a diverse portfolio that includes diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. The company sells its products globally, serving various healthcare sectors and addressing the needs of patients, healthcare providers, and consumers.
Additional Information
Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is pivotal in the healthcare sector. Its diagnostic solutions are essential for medical testing, while its medical devices enhance patient care. The nutritional segment, with brands like Similac and Ensure, supports health across demographics, making Abbott a key player in advancing healthcare and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
114,000
CEO
Mr. Robert B. Ford
Country
United States
IPO Year
1983
Website
www.abbott.comAbbott Laboratories (ABT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Abbott (ABT) Stock Moves -0.15%: What You Should Know
In the closing of the recent trading day, Abbott (ABT) stood at $131.30, denoting a -0.15% change from the preceding trading day.
May 23, 2025
By Zacks Equity Research
Tale of the Tape
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
May 23, 2025
By Zacks Equity Research
Realtime BLOG
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
May 22, 2025
By Urmimala Biswas
Analyst Blog
Latest News
Quick Summary
Analyst recommendations from brokerage firms significantly impact stock prices, as media reports on rating changes often sway investor decisions on buying, selling, or holding.
Why It Matters
Analyst recommendations can significantly sway stock prices, impacting investment decisions and market trends, making them a critical factor in investment strategy.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Abbott (ABT) is currently a focal point for Zacks.com users, indicating increased interest and potential developments in the stock's outlook.
Why It Matters
Increased interest in Abbott (ABT) suggests potential volatility or opportunities, indicating that market sentiment may shift and influence stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stifel's Barry Bannister is a highly regarded voice on Wall Street, known for his insights and analyses that investors trust.
Why It Matters
Barry Bannister's insights carry weight on Wall Street, indicating his opinions may influence market trends and investor decisions.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
ABT's Libre technology, per REFLECT studies, is the first continuous glucose monitor linked to reduced hospitalizations for heart complications in diabetes patients.
Why It Matters
ABT's Libre technology reducing hospitalizations for heart complications in diabetes patients suggests potential for increased sales and market share, positively impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Passive income relies on effective investment alternatives to generate earnings with minimal effort. Investors should explore viable options for generating such income.
Why It Matters
The emphasis on passive income highlights the demand for reliable investment options, signaling potential growth in sectors offering such alternatives.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Abbott India reported a 28% increase in fourth-quarter profit, driven by strong demand for gastrointestinal and anti-infective medications.
Why It Matters
Abbott India's 28% profit rise indicates strong market demand, suggesting robust sales growth and potential for future earnings, positively influencing investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About ABT Stock
What is Abbott Laboratories's (ABT) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Abbott Laboratories (ABT) has a median price target of $143.12. The highest price target is $159.00 and the lowest is $120.12.
Is ABT stock a good investment in 2025?
According to current analyst ratings, ABT has 19 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $131.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABT stock?
Wall Street analysts predict ABT stock could reach $143.12 in the next 12 months. This represents a 9.0% increase from the current price of $131.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Abbott Laboratories's business model?
Abbott Laboratories generates revenue through a diverse portfolio that includes diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. The company sells its products globally, serving various healthcare sectors and addressing the needs of patients, healthcare providers, and consumers.
What is the highest forecasted price for ABT Abbott Laboratories?
The highest price target for ABT is $159.00 from Matt Miksic at Barclays, which represents a 21.1% increase from the current price of $131.30.
What is the lowest forecasted price for ABT Abbott Laboratories?
The lowest price target for ABT is $120.12 from at , which represents a -8.5% decrease from the current price of $131.30.
What is the overall ABT consensus from analysts for Abbott Laboratories?
The overall analyst consensus for ABT is bullish. Out of 34 Wall Street analysts, 19 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $143.12.
How accurate are ABT stock price projections?
Stock price projections, including those for Abbott Laboratories, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 2:01 AM UTC